Single Nucleotide Polymorphism Genotyping Market – Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028 Segmented By Technology (TaqMan SNP Genotyping, Massarray SNP Genotyping, SNP GeneChip Arrays, Others), By Application (Animal Genetics, Plant Improvement, Diagnostic Research, Pharmaceuticals and Pharmacogenomics, Agricultural Biotechnology, Others), by region, and Competition

  • Industry : Healthcare
  • Pages : NA
  • Published Date : NA
Customization Enquiry

Buy Now

Summary

Report Description

Forecast Period

2024-2028

Market Size (2022)

USD 8.15 billion

CAGR (2024-2028)

17.20%

Fastest Growing Segment

TaqMan SNP Genotyping

Largest Market

North America

 

Market Overview

Global Single Nucleotide Polymorphism Genotyping Market has valued at USD 8.15 billion in 2022 and is anticipated to witness an impressive growth in the forecast period with a CAGR of 17.20% through 2028. Single Nucleotide Polymorphism Genotyping, often abbreviated as SNP Genotyping, is a molecular biology technique used to identify and analyze single nucleotide polymorphisms (SNPs) within an individual's DNA. SNPs are the most common type of genetic variation in the human genome and in the genomes of many other species. They involve a single base pair change in the DNA sequence, such as a substitution of one nucleotide (A, T, C, or G) for another at a specific position in the genome. SNP genotyping is a critical tool in genetics and genomics research, clinical diagnostics, and various other applications. SNP genotyping begins with the identification of specific SNPs of interest. These SNPs can be associated with traits, diseases, drug responses, or other genetic variations. They are typically selected based on their potential biological or clinical relevance. To perform SNP genotyping, a DNA sample from an individual or organism is required. This can be obtained from various sources, such as blood, saliva, buccal swabs, or tissue samples. The DNA is typically purified and extracted from the sample.

The field of pharmacogenomics uses genetic data, often obtained through SNP genotyping, to optimize drug selection and dosages. This is especially important for medications with a narrow therapeutic index. SNP genotyping is essential in drug development. It aids in identifying drug targets, stratifying patient populations in clinical trials, and ensuring the safety and efficacy of pharmaceutical products. SNP genotyping is used in forensic analysis to identify individuals and establish relationships. Ancestry testing companies use SNPs to provide insights into one's genetic heritage. Ongoing advancements in genotyping technologies, such as high-throughput genotyping and next-generation sequencing, have made SNP genotyping more efficient, cost-effective, and accessible. The sharing of genetic data and collaborative research efforts have accelerated discoveries in genomics, further fueling the demand for SNP genotyping.

Key Market Drivers

Technological Advancements

Next-Generation Sequencing (NGS) technologies, such as Illumina's sequencing platforms, have revolutionized genotyping. NGS allows for the simultaneous genotyping of thousands to millions of SNPs in a single experiment, making it a powerful tool for genome-wide association studies (GWAS) and other applications. DNA microarrays are used to simultaneously genotype thousands of SNPs. They offer a high-throughput and cost-effective approach to genotyping. Microarray-based platforms like Affymetrix and Illumina have gained widespread adoption. Real-time PCR-based assays, like TaqMan and allele-specific PCR, are used for SNP genotyping. These assays offer high specificity, sensitivity, and real-time data acquisition, making them valuable in research and clinical settings.

Digital PCR technology enables absolute quantification of target DNA molecules, including SNP alleles. It is highly precise and can detect rare alleles or variants with high accuracy. Mass spectrometry-based genotyping methods, such as MALDI-TOF (Matrix-Assisted Laser Desorption/Ionization-Time of Flight), are used to analyze SNP alleles. These methods offer high throughput and accuracy. Allele-Specific Oligonucleotide Ligation Assay (ASO-LA) techniques involve hybridizing SNP-specific oligonucleotides with target DNA, followed by ligation of SNP-specific probes. This method is highly specific and can be used in multiplex format. Automation and robotics have enabled high-throughput SNP genotyping. These platforms, like Fluidigm's Biomark and Bio-Rad's BioMark HD, are suitable for large-scale genotyping projects. The use of nanotechnology, such as nanowires and nanoparticles, has been explored to improve the sensitivity and specificity of SNP genotyping assays. The CRISPR-Cas system can be adapted for SNP genotyping by designing guide RNAs that specifically target SNP sites. It allows for precise and multiplexed genotyping.

Advances in data analysis and bioinformatics tools have become crucial. Software for SNP calling, haplotype phasing, and interpretation of genotyping data has improved. The integration of SNP genotyping with single-cell analysis has allowed researchers to explore genetic diversity at the individual cell level, providing insights into clonal evolution and tissue heterogeneity. Efforts are ongoing to develop portable and point-of-care genotyping devices that can rapidly analyze SNP data at the bedside or in resource-limited settings. Advances in sample preparation techniques have reduced the time and cost associated with DNA extraction and purification, making genotyping more efficient. This factor will help in the development of the Global Single Nucleotide Polymorphism Genotyping Market.

Increase Demand in Forensic Science and Ancestry Testing

SNP genotyping is used in forensic DNA analysis to identify individuals, such as in criminal investigations. SNPs are highly polymorphic and can help distinguish one individual from another, even within a close biological relationship. SNPs can be used to analyze evidence collected from crime scenes, such as blood, hair, or other bodily fluids, to determine the genetic profile of a suspect or victim. SNP genotyping technology has been instrumental in solving cold cases by reexamining evidence from unsolved crimes, sometimes years or decades later. In cases where biological relationships need to be confirmed (e.g., paternity, or maternity testing), SNP genotyping can be used to establish family connections with a high degree of accuracy. In forensic anthropology and archaeology, SNP genotyping is used to identify human remains, especially in mass disasters or historical investigations.

Ancestry testing services, like 23andMe and Ancestry.com, utilize SNP genotyping to provide customers with information about their genetic heritage, including ancestral origins, migration patterns, and family tree connections. Consumers are interested in learning more about their heritage and ethnic background. SNP genotyping helps individuals trace their genetic roots and discover their ancestral origins. Ancestry testing relies on large reference databases of SNP data to compare an individual's genetic markers to global populations, allowing for estimates of the person's ancestry. Some ancestry testing services also offer insights into genetic health risks and inherited traits. SNP data is used to provide these personalized genetic reports. This factor will pace up the demand of the Global Single Nucleotide Polymorphism Genotyping Market

Rise in Drug Development

Identifying appropriate drug targets is a fundamental step in drug development. Single Nucleotide Polymorphism (SNP) genotyping is used to discover genetic variations associated with specific diseases, making it easier to identify potential drug targets. Understanding the genetic basis of a disease allows researchers to develop drugs that target the underlying causes. Drug development often involves clinical trials to test the safety and efficacy of new medications. Single Nucleotide Polymorphism genotyping helps stratify patient populations based on their genetic profiles, ensuring that the right patients are enrolled in clinical trials. This can increase the chances of success and lead to more personalized treatment approaches. Single Nucleotide Polymorphism genotyping is essential for pharmacogenomic studies, which examine how an individual's genetic makeup influences their response to drugs. This knowledge is critical for tailoring drug treatments to individual patients, optimizing dosages, and minimizing adverse reactions. Single Nucleotide Polymorphism genotyping can help predict how certain individuals might react to a drug, including whether they are at risk for adverse events. This information is invaluable in assessing a drug's safety profile. Single Nucleotide Polymorphism genotyping can be used to determine whether certain genetic variants in patients affect the drug's efficacy. This information can guide dosing adjustments and the selection of alternative treatments for non-responders.

Single Nucleotide Polymorphism genotyping is used to discover and validate biomarkers related to drug responses and treatment outcomes. These biomarkers can help streamline drug development and improve the accuracy of clinical trial results. Single Nucleotide Polymorphism genotyping is applied in animal models and preclinical studies to better understand how genetic factors influence drug metabolism, toxicity, and efficacy. In some cases, SNP genotyping is used to develop companion diagnostics that are paired with specific drugs to identify patients who are most likely to benefit from those treatments. This precision medicine approach is increasingly important in drug development. Regulatory agencies, such as the U.S. Food and Drug Administration (FDA), increasingly require pharmacogenomic data, including Single Nucleotide Polymorphism genotyping information, in drug submissions. This ensures that genetic factors are considered in drug development and safety assessments. By incorporating Single Nucleotide Polymorphism genotyping data, clinical trial designs can be optimized to maximize the chances of successful drug development, reduce costs, and accelerate the path to market. This factor will accelerate the demand of the Global Single Nucleotide Polymorphism Genotyping Market

Download Free Sample Report

Key Market Challenges

Cost and Accessibility

Many SNP genotyping technologies, such as next-generation sequencing (NGS) and microarrays, involve substantial costs for equipment, reagents, and data analysis. This can be a barrier for research institutions, clinical laboratories, and smaller companies with limited budgets. Ongoing costs related to reagents, consumables, and maintenance can be a significant financial burden. The high cost per sample for some genotyping methods may limit their use, especially in large-scale projects. While the cost of genotyping instruments has come down, the complexity of data analysis and the need for high-performance computing infrastructure can still be expensive. Effective bioinformatics support is often required to derive meaningful insights from genotyping data. The genotyping market has seen increased competition, which has driven companies to offer more cost-effective solutions. However, this competition can lead to market saturation, making it challenging for companies to differentiate their products based on cost. In resource-constrained settings, such as low- and middle-income countries, the high cost of genotyping technologies can limit access to advanced genetic testing and research capabilities. Access to SNP genotyping services and technologies can be limited in rural or remote areas, where advanced laboratories and infrastructure may not be available.

Complexity of Genetic Variations

The human genome is highly diverse, with millions of SNPs and other genetic variants spread across the genome. Understanding how specific SNPs are associated with traits, diseases, or drug responses can be challenging due to this inherent genetic heterogeneity. Rare and novel SNPs, which are not well-represented in reference databases, can be particularly challenging to identify and interpret. These variants may have important clinical implications, but their rarity makes them less accessible for genotyping and research. SNPs in close physical proximity on a chromosome can exhibit linkage disequilibrium, meaning they are inherited together. Interpreting the functional impact of a single SNP may require considering its relationships with neighboring SNPs. Genetic interactions, where the effect of one SNP is dependent on the presence of another SNP, can add complexity to genetic studies. Detecting and characterizing such interactions requires large datasets and sophisticated analytical methods. While SNP genotyping primarily focuses on single-nucleotide changes, structural variations like Copy Number Variations (CNVs) can also influence genetic traits and disease susceptibility. These require specialized genotyping and analysis methods. Many complex traits, including common diseases, are influenced by multiple SNPs and genes, as well as environmental factors. Untangling the contribution of individual SNPs in such contexts is intricate. Understanding the functional significance of SNPs, such as their impact on gene expression or protein function, is an ongoing challenge. Variants in non-coding regions can have important regulatory roles.

Key Market Trends

Agriculture and Biotechnology

 SNP genotyping is used to identify specific genetic markers associated with desirable traits in crops, such as disease resistance, yield, and nutritional content. Genomic selection techniques help breeders make informed decisions about which plants to select for further breeding. SNP markers are employed in marker-assisted breeding programs to accelerate the development of new crop varieties with improved characteristics. This approach reduces the time required to develop and release new, high-performing crop varieties. Identifying SNP markers associated with disease resistance allows breeders to develop crop varieties that are more resilient to pests and pathogens, reducing the need for chemical interventions. SNP genotyping is applied to improve the genetic traits of livestock, including meat and dairy animals. Breeders use SNP data to select animals with the desired traits, such as growth rate, milk production, and disease resistance. SNP genotyping can be used to preserve and conserve the genetic diversity of livestock breeds, especially those at risk of extinction. Identifying SNP markers associated with disease resistance in livestock can reduce the economic losses associated with disease outbreaks and decrease the use of antibiotics. Biotechnological research often relies on SNP genotyping to understand the role of specific genetic variations in cellular processes, gene expression, and protein function. SNP genotyping data is used to identify associations between genetic variations and specific phenotypes, contributing to a deeper understanding of complex traits.

Segmental Insights

Technology Insights

In 2022, the Global Single Nucleotide Polymorphism Genotyping Market largest share was held by TaqMan SNP Genotyping segment and is predicted to continue expanding over the coming years. TaqMan SNP genotyping is a well-established and widely recognized genotyping technology. It has a proven track record for its accuracy and reliability in SNP detection. Researchers and laboratories often choose familiar and trusted technologies like TaqMan for their genotyping needs. TaqMan assays are known for their high specificity and sensitivity in detecting single nucleotide polymorphisms. This accuracy is critical in various applications, including genetics research, clinical diagnostics, and pharmaceutical development. TaqMan SNP genotyping assays can be customized to target specific SNPs of interest. This flexibility is valuable for researchers and clinical laboratories that want to study and monitor genetic variations. TaqMan SNP genotyping is scalable, making it suitable for handling both small and large sample sizes. This versatility allows laboratories to adapt their genotyping efforts to different research or diagnostic needs. TaqMan assays are well-suited for automation, making them efficient for processing a high volume of samples. This automation capability is particularly important in clinical and research settings where large-scale genotyping is required. Many laboratories and institutions have already invested in TaqMan-based genotyping platforms and instruments. This existing infrastructure makes it convenient for them to continue using TaqMan technology, and they may be more inclined to expand their use of TaqMan assays for SNP genotyping.

Application Insights

In 2022, the Global Single Nucleotide Polymorphism Genotyping Market largest share was held by Pharmaceuticals and Pharmacogenomics segment and is predicted to continue expanding over the coming years.  The pharmaceutical industry heavily relies on SNP genotyping to develop new drugs and tailor existing medications to individual genetic profiles. Pharmacogenomics, which studies how genetic variations impact drug responses, is a critical application. Understanding the genetic basis of drug efficacy and safety is essential for designing personalized treatment plans. Pharmaceutical companies use SNP genotyping to stratify patient populations in clinical trials. By identifying genetic factors that may affect drug responses, they can optimize trial designs, potentially increase the likelihood of success, and meet regulatory requirements for precision medicine trials. SNP genotyping helps identify potential drug targets by revealing genetic variations associated with specific diseases. This information is valuable for pharmaceutical companies in the early stages of drug discovery. SNP genotyping is used to discover and validate biomarkers that can predict disease risk or prognosis. In drug development, biomarkers play a critical role in patient stratification and treatment decisions. SNP genotyping is integral to companion diagnostics, where genetic tests are used alongside specific drugs to determine the most suitable treatment for an individual. This approach ensures the right patients receive the right medications.


Download Free Sample Report

Regional Insights

The North America region dominates the Global Single Nucleotide Polymorphism Genotyping Market in 2022. North America, particularly the United States and Canada, has a strong tradition of scientific research and innovation. Many renowned research institutions, universities, and biotechnology companies are based in this region. These institutions drive SNP genotyping research and technological advancements. North America has a substantial investment in healthcare and biotechnology. Government funding, private investment, and venture capital play significant roles in supporting research and development in genomics and genetics. The region has access to state-of-the-art genotyping technologies and equipment. Leading companies in the genotyping industry, such as Illumina, Thermo Fisher Scientific, and Affymetrix (acquired by Thermo Fisher), are headquartered or have a strong presence in North America. North America is home to a sizable biopharmaceutical industry. SNP genotyping is essential for drug development, pharmacogenomics, and clinical trials. This proximity to pharmaceutical companies drives demand for SNP genotyping services and technologies. Government initiatives and research projects related to genetics, genomics, and personalized medicine contribute to the growth of the SNP genotyping market. The National Institutes of Health (NIH) and various Canadian research agencies fund many genomics projects.

Recent Developments

  • In March 2021, the quadricep tendon has been added to the AlloConnex range of tendons, ligaments, and fascia by AlloSource, one of the leading allograft providers in the United States. AlloSource develops cutting-edge cellular and tissue allografts to assist surgeons in healing their patients. Recently, it has become more common to repair ligaments using a quadricep tendon. AlloSource's AlloConnex quadricep tendon, which is offered with or without the bone block for different surgical approaches, is a reliable solution for cruciate ligament surgeries. A wide range of operations that surgeons carry out are supported by the AlloConnex tendon and ligament portfolio. In addition to the novel quadricep tendon, the AlloConnex portfolio of specialised allografts also includes the patellar ligaments, Achilles, anterior tibialis, gracilis, peroneus longus, posterior tibialis, and semitendinosus tendons. The tendon supply offered by AlloSource consists of single strand, double strand, and pre-shaped variants.
  • In February 2021, Thermo Fisher Scientific, the global leader in scientific solutions, has unveiled the Applied Biosystems TaqMan SARS-CoV-2 Mutation Panel. This panel offers a customizable selection of 22 verified real-time PCR assays designed for the identification of SARS-CoV-2 mutations. These assays empower the monitoring of variants responsible for COVID-19 infections in specific regions worldwide and grant laboratories the flexibility to select the mutations they wish to track. Given the numerous mutations in SARS-CoV-2, some of which may affect the efficacy of treatments and vaccines, ongoing surveillance of viral changes is of paramount importance. The TaqMan SARS-CoV-2 Mutation Panel is highly adaptable, capable of analysing a small or large number of samples to identify one or multiple mutations. This versatility allows laboratories to meet varying testing requirements using the real-time PCR instruments they already have. The panel delivers results in approximately one hour and utilizes the reliable TaqMan SNP genotyping assay technology, ensuring efficient mutation detection and differentiation.

Key Market Players

  • Agilent Technologies Inc.
  • Bio-Rad Laboratories Inc.
  • Danaher Corporation
  • Douglas Scientific LLC
  • Illumina Inc.
  • Life Technologies Corp.
  • Luminex Corp
  •  Promega Corporation
  • Thermo Fischer Scientific Inc.
  • Fluidigm Corporation

 

By Technology

By Application

By Region
  • TaqMan SNP Genotyping
  • Massarray SNP Genotyping
  • SNP GeneChip Arrays
  • Others
  • Animal Genetics
  • Plant Improvement
  • Diagnostic Research
  • Pharmaceuticals and Pharmacogenomics
  • Agricultural Biotechnology
  • Others
  • North America
  • Asia-Pacific
  • Europe
  • South America
  • Middle East & Africa

 

Report Scope:

In this report, the Global Single Nucleotide Polymorphism Genotyping Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

  • Single Nucleotide Polymorphism Genotyping Market, By Technology:

o   TaqMan SNP Genotyping

o   Massarray SNP Genotyping

o   SNP GeneChip Arrays

o   Others

  • Single Nucleotide Polymorphism Genotyping Market, By Application:

o   Animal Genetics

o   Plant Improvement

o   Diagnostic Research

o   Pharmaceuticals and Pharmacogenomics

o   Agricultural Biotechnology

o   Others

  • Single Nucleotide Polymorphism Genotyping Market, By region:

o   North America

§  United States

§  Canada

§  Mexico

o   Asia-Pacific

§  China

§  India

§  South Korea

§  Australia

§  Japan

o   Europe

§  Germany

§  France

§  United Kingdom

§  Spain

§  Italy

o   South America

§  Brazil

§  Argentina

§  Colombia

o   Middle East & Africa

§  South Africa

§  Saudi Arabia

§  UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Single Nucleotide Polymorphism Genotyping Market.

Available Customizations:

Global Single Nucleotide Polymorphism Genotyping Market report with the given market data, Tech Sci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Global Single Nucleotide Polymorphism Genotyping Market is an upcoming report to be released soon. If you wish an early delivery of this report or want to confirm the date of release, please contact us at [email protected]               

Table of content

1.    Product Overview

1.1.  Market Definition

1.2.  Scope of the Market

1.2.1.     Markets Covered

1.2.2.     Years Considered for Study

1.2.3.     Key Market Segmentations

2.    Research Methodology

2.1.  Objective of the Study

2.2.  Baseline Methodology

2.3.  Key Industry Partners

2.4.  Major Association and Secondary Applications

2.5.  Forecasting Methodology

2.6.  Data Triangulation & Validation

2.7.  Assumptions and Limitations

3.    Executive Summary

3.1.  Overview of the Market

3.2.  Overview of Key Market Segmentations

3.3.  Overview of Key Market Players

3.4.  Overview of Key Regions/Countries

3.5.  Overview of Market Drivers, Challenges, Trends

4.    Voice of Customer

5.    Global Single Nucleotide Polymorphism Genotyping Market Outlook

5.1.  Market Size & Forecast

5.1.1.     By Value

5.2.  Market Share & Forecast

5.2.1.     By Technology (TaqMan SNP Genotyping, Massarray SNP Genotyping, SNP GeneChip Arrays, Others)

5.2.2.     By Application (Animal Genetics, Plant Improvement, Diagnostic Research, Pharmaceuticals and Pharmacogenomics, Agricultural Biotechnology, Others)

5.2.3.     By Region

5.2.4.     By Company (2022)

5.3.  Market Map

6.    Asia Pacific Single Nucleotide Polymorphism Genotyping Market Outlook

6.1.  Market Size & Forecast

6.1.1.     By Value

6.2.  Market Share & Forecast

6.2.1.     By Technology

6.2.2.     By Application

6.2.3.     By Country

6.3.  Asia Pacific: Country Analysis

6.3.1.     China Single Nucleotide Polymorphism Genotyping Market Outlook

6.3.1.1.         Market Size & Forecast

6.3.1.1.1.             By Value

6.3.1.2.         Market Share & Forecast

6.3.1.2.1.             By Technology

6.3.1.2.2.             By Application

6.3.2.     India Single Nucleotide Polymorphism Genotyping Market Outlook

6.3.2.1.         Market Size & Forecast

6.3.2.1.1.             By Value

6.3.2.2.         Market Share & Forecast

6.3.2.2.1.             By Technology

6.3.2.2.2.             By Application

6.3.3.     Australia Single Nucleotide Polymorphism Genotyping Market Outlook

6.3.3.1.         Market Size & Forecast

6.3.3.1.1.             By Value

6.3.3.2.         Market Share & Forecast

6.3.3.2.1.             By Technology

6.3.3.2.2.             By Application

6.3.4.     Japan Single Nucleotide Polymorphism Genotyping Market Outlook

6.3.4.1.         Market Size & Forecast

6.3.4.1.1.             By Value

6.3.4.2.         Market Share & Forecast

6.3.4.2.1.             By Technology

6.3.4.2.2.             By Application

6.3.5.     South Korea Single Nucleotide Polymorphism Genotyping Market Outlook

6.3.5.1.         Market Size & Forecast

6.3.5.1.1.             By Value

6.3.5.2.         Market Share & Forecast

6.3.5.2.1.             By Technology

6.3.5.2.2.             By Application

7.    Europe Single Nucleotide Polymorphism Genotyping Market Outlook

7.1.  Market Size & Forecast

7.1.1.     By Value

7.2.  Market Share & Forecast

7.2.1.     By Technology

7.2.2.     By Application

7.2.3.     By Country

7.3.  Europe: Country Analysis

7.3.1.     France Single Nucleotide Polymorphism Genotyping Market Outlook

7.3.1.1.         Market Size & Forecast

7.3.1.1.1.             By Value

7.3.1.2.         Market Share & Forecast

7.3.1.2.1.             By Technology

7.3.1.2.2.             By Application

7.3.2.     Germany Single Nucleotide Polymorphism Genotyping Market Outlook

7.3.2.1.         Market Size & Forecast

7.3.2.1.1.             By Value

7.3.2.2.         Market Share & Forecast

7.3.2.2.1.             By Technology

7.3.2.2.2.             By Application

7.3.3.     Spain Single Nucleotide Polymorphism Genotyping Market Outlook

7.3.3.1.         Market Size & Forecast

7.3.3.1.1.             By Value

7.3.3.2.         Market Share & Forecast

7.3.3.2.1.             By Technology

7.3.3.2.2.             By Application

7.3.4.     Italy Single Nucleotide Polymorphism Genotyping Market Outlook

7.3.4.1.         Market Size & Forecast

7.3.4.1.1.             By Value

7.3.4.2.         Market Share & Forecast

7.3.4.2.1.             By Technology

7.3.4.2.2.             By Application

7.3.5.     United Kingdom Single Nucleotide Polymorphism Genotyping Market Outlook

7.3.5.1.         Market Size & Forecast

7.3.5.1.1.             By Value

7.3.5.2.         Market Share & Forecast

7.3.5.2.1.             By Technology

7.3.5.2.2.             By Application

8.    North America Single Nucleotide Polymorphism Genotyping Market Outlook

8.1.  Market Size & Forecast

8.1.1.     By Value

8.2.  Market Share & Forecast

8.2.1.     By Technology

8.2.2.     By Application

8.2.3.     By Country

8.3.  North America: Country Analysis

8.3.1.     United States Single Nucleotide Polymorphism Genotyping Market Outlook

8.3.1.1.         Market Size & Forecast

8.3.1.1.1.             By Value

8.3.1.2.         Market Share & Forecast

8.3.1.2.1.             By Technology

8.3.1.2.2.             By Application

8.3.2.     Mexico Single Nucleotide Polymorphism Genotyping Market Outlook

8.3.2.1.         Market Size & Forecast

8.3.2.1.1.             By Value

8.3.2.2.         Market Share & Forecast

8.3.2.2.1.             By Technology

8.3.2.2.2.             By Application

8.3.3.     Canada Single Nucleotide Polymorphism Genotyping Market Outlook

8.3.3.1.         Market Size & Forecast

8.3.3.1.1.             By Value

8.3.3.2.         Market Share & Forecast

8.3.3.2.1.             By Technology

8.3.3.2.2.             By Application

9.    South America Single Nucleotide Polymorphism Genotyping Market Outlook

9.1.  Market Size & Forecast

9.1.1.     By Value

9.2.  Market Share & Forecast

9.2.1.     By Technology

9.2.2.     By Application

9.2.3.     By Country

9.3.  South America: Country Analysis

9.3.1.     Brazil Single Nucleotide Polymorphism Genotyping Market Outlook

9.3.1.1.         Market Size & Forecast

9.3.1.1.1.             By Value

9.3.1.2.         Market Share & Forecast

9.3.1.2.1.             By Technology

9.3.1.2.2.             By Application

9.3.2.     Argentina Single Nucleotide Polymorphism Genotyping Market Outlook

9.3.2.1.         Market Size & Forecast

9.3.2.1.1.             By Value

9.3.2.2.         Market Share & Forecast

9.3.2.2.1.             By Technology

9.3.2.2.2.             By Application

9.3.3.     Colombia Single Nucleotide Polymorphism Genotyping Market Outlook

9.3.3.1.         Market Size & Forecast

9.3.3.1.1.             By Value

9.3.3.2.         Market Share & Forecast

9.3.3.2.1.             By Technology

9.3.3.2.2.             By Application

10.  Middle East and Africa Single Nucleotide Polymorphism Genotyping Market Outlook

10.1.              Market Size & Forecast

10.1.1.  By Value

10.2.              Market Share & Forecast

10.2.1.  By Technology

10.2.2.  By Application

10.2.3.  By Country

10.3.              MEA: Country Analysis

10.3.1.  South Africa Single Nucleotide Polymorphism Genotyping Market Outlook

10.3.1.1.      Market Size & Forecast

10.3.1.1.1.           By Value

10.3.1.2.      Market Share & Forecast

10.3.1.2.1.           By Technology

10.3.1.2.2.           By Application

10.3.2.  Saudi Arabia Single Nucleotide Polymorphism Genotyping Market Outlook

10.3.2.1.      Market Size & Forecast

10.3.2.1.1.           By Value

10.3.2.2.      Market Share & Forecast

10.3.2.2.1.           By Technology

10.3.2.2.2.           By Application

10.3.3.  UAE Single Nucleotide Polymorphism Genotyping Market Outlook

10.3.3.1.      Market Size & Forecast

10.3.3.1.1.           By Value

10.3.3.2.      Market Share & Forecast

10.3.3.2.1.           By Technology

10.3.3.2.2.           By Application

11.  Market Dynamics

11.1.              Drivers

11.2.              Challenges

12.  Market Trends & Developments

12.1.              Recent Developments

12.2.              Product Launches

12.3.              Mergers & Acquisitions

13.  Global Single Nucleotide Polymorphism Genotyping Market : SWOT Analysis

14.  Porter’s Five Forces Analysis

14.1.              Competition in the Industry

14.2.              Potential of New Entrants

14.3.              Power of Suppliers

14.4.              Power of Customers

14.5.              Threat of Substitute Product

15.  PESTLE Analysis

16.  Competitive Landscape

16.1.              Agilent Technologies Inc.

16.1.1.  Business Overview

16.1.2.  Company Snapshot

16.1.3.  Products & Services

16.1.4.  Financials (As Reported)

16.1.5.  Recent Developments

16.2.              Bio-Rad Laboratories Inc.

16.3.              Danaher Corporation

16.4.              Douglas Scientific LLC

16.5.              Illumina Inc.

16.6.              Life Technologies Corp.

16.7.              Luminex Corp.

16.8.              Promega Corporation

16.9.              Thermo Fischer Scientific Inc.

16.10.           Fluidigm Corporation

17.  Strategic Recommendations

18.   About Us & Disclaimer

Figures and Tables

Frequently asked questions

down-arrow

The market size of the Single Nucleotide Polymorphism Genotyping Market was estimated to be USD 8.15 billion in 2022.

down-arrow

Agilent Technologies Inc., Eurofins Genomics (Eurofins Scientific SE), Illumina Inc. are some of the key players operating in the Single Nucleotide Polymorphism Genotyping Market.

down-arrow

Reducing the cost of SNP genotyping to make it more accessible to a wider population is an ongoing challenge.

down-arrow

The growing interest in personalized medicine has increased the demand for SNP genotyping.

Related Reports

profile

Sakshi Bajaal

Business Consultant
Press Release

Global Single Nucleotide Polymorphism Genotyping Market to grow with a CAGR of 17.20 %

Jan, 2024

Increasing healthcare infrastructure and a supportive regulatory environment are the major drivers for the Global Single Nucleotide Polymorphism Genotyping Market.

Why Choose Us